MLND News and Press, Millendo Therapeutics From 06/21/19

Quick Take BridgeBio ( BBIO ) has filed to raise gross proceeds of up to $225 million from a U.S. IPO, according to an S-1/A registration statement . The group is developing therapeutics for Mendelian diseases, or diseases arising from defects in a single gene as well as cancers with clea...

Millendo Therapeutics, Inc. (Nasdaq: MLND), a clinical-stage biopharmaceutical company developing novel treatments for orphan endocrine diseases, today announced that Pharis Mohideen, M.D., is departing the company to pursue a career opportunity closer to his home in New Jersey, allowing h...

Millendo Therapeutics, Inc. (Nasdaq: MLND), a clinical-stage biopharmaceutical company developing novel treatments for orphan endocrine diseases, announced today that Julia C. Owens, Ph.D., President and Chief Executive Officer, will present at the Jefferies 2019 Healthcare Conference in N...

Millendo Therapeutics (NASDAQ: MLND ): Q1 GAAP EPS of -$0.78  misses by $0.08 . More news on: Millendo Therapeutics, Inc., Earnings news and commentary, , Read more ...

– Initiated pivotal study of livoletide in Prader-Willi syndrome (PWS) – – Established foundation for a commercial organization in Boston – – Protocol amendment underway for nevanimibe study in congenital adrenal hyperplasia (CAH) – ...

The following slide deck was published by Millendo Therapeutics, Inc. in conjunction with this Read more ...

Millendo Therapeutics, Inc. (Nasdaq: MLND), a clinical-stage biopharmaceutical company developing novel treatments for orphan endocrine diseases, announced today that its late-stage clinical candidates, livoletide and nevanimibe, will be featured in three concurrent poster presentations at...

Millendo Therapeutics, Inc. (Nasdaq: MLND), a clinical-stage biopharmaceutical company developing novel treatments for orphan endocrine diseases, today announced that management will present company overviews at the following healthcare investor conferences: 2019 SunTrust Robinson H...

Millendo Therapeutics, Inc. (Nasdaq: MLND), a clinical-stage biopharmaceutical company developing novel treatments for orphan endocrine diseases, announced today that Julia C. Owens, Ph.D., President and Chief Executive Officer, will present at the 18th Annual Needham Healthcare Conference...

Millendo Therapeutics (NASDAQ: MLND ): FY GAAP EPS of -$17.58. More news on: Millendo Therapeutics, Inc., Earnings news and commentary, , Read more ...